Acute Repetitive Seizures Market Forecasts to 2030 – Global Analysis By Product (Diastat Rectal Gel, AZ-002, NRL-1, USL-261 and Other Products), Drug Type, Route of Administration, Distribution Channel, End User and By Geography
According to Stratistics MRC, the Global Acute Repetitive Seizures Market is accounted for $2.9 billion in 2023 and is expected to reach $7.6 billion by 2030 growing at a CAGR of 14.4% during the forecast period. Acute Repetitive Seizures (ARS) is a series of epileptic seizures that occur in rapid succession within a relatively short period, typically within 24 hours. These seizures are characterized by their repetitive nature and can occur despite the person's normal seizure control measures, such as medication adherence. They can occur in various types of epilepsy and may require urgent medical attention to manage and prevent further seizures, as they can be dangerous and potentially life-threatening if not controlled promptly.
According to World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide.
Market Dynamics:Driver:Rising prevalence of epilepsy
The market is witnessing a concerning rise in epilepsy prevalence. This trend indicates a growing population affected by recurrent and unpredictable seizures, necessitating advanced therapeutic interventions and management strategies. The surge in epilepsy cases within the sector underscores the pressing need for innovative treatments, personalized care plans, and heightened awareness campaigns to address the complex challenges faced by individuals grappling with this neurological disorder.
Restraint:Lack of awareness
Despite significant advancements in epilepsy treatment, there remains a notable lack of awareness in the market. Many individuals, including healthcare providers and the general public, may not fully grasp the challenges faced by patients or the available therapeutic options. This gap in awareness hinders timely diagnosis, appropriate management, and access to innovative treatments, highlighting the need for targeted education and advocacy efforts to improve outcomes in management.
Opportunity:Development of new drugs
Research is geared towards novel mechanisms of action, such as targeting specific ion channels or neurotransmitter systems implicated in seizure generation. Additionally, advancements in drug delivery methods, like intranasal or transdermal formulations, aim to improve patient compliance and treatment outcomes. These efforts signify a proactive approach to optimizing therapeutic options for individuals with the market.
Threat:High cost of treatment
The high cost of treatment in the Acute Repetitive Seizures (ARS) market is a significant concern, often exceeding the financial capacities of patients and healthcare systems alike. The expenses encompass diagnostic tests, medications, hospitalizations, and ongoing monitoring, creating a considerable financial burden. This cost barrier can limit access to essential therapies, impacting patient outcomes and quality of life.
Covid-19 Impact:
The COVID-19 pandemic significantly impacted the Acute Repetitive Seizures (ARS) market. Access to healthcare services was disrupted, leading to delayed diagnosis and treatment for many patients. Clinical trials and research initiatives also faced setbacks, affecting the development of new therapies. However, telemedicine and remote monitoring gained traction, offering alternative ways to manage patients.
The barbiturates segment is expected to be the largest during the forecast period
The barbiturates segment is expected to be the largest during the forecast period. Barbiturates have been a longstanding option, but their use has declined due to safety concerns and the development of newer, more effective medications. In the market, they occupy a niche role for specific cases where other treatments have failed or are contraindicated. Despite their limited use, barbiturates like phenobarbital remain a viable option for certain patients, particularly in resource-limited settings or when tailored to individual patient needs.
The home care settings segment is expected to have the highest CAGR during the forecast period
The home care settings segment is expected to have the highest CAGR during the forecast period. These settings encompass a range of services, including monitoring equipment, caregiver training, and emergency response plans. With advancements in telemedicine and remote monitoring technologies, home care settings have become increasingly sophisticated, enabling real-time interventions and improving patient outcomes while enhancing convenience and comfort for individuals managing acute repetitive seizures.
Region with largest share:North America is projected to hold the largest market share during the forecast period driven by factors such as increasing awareness, improved diagnostic technologies, and a growing patient population. Key players in this market focus on developing advanced therapies and medications to address unmet medical needs. Additionally, government initiatives and healthcare reforms are playing a crucial role in enhancing access to ARS treatments, leading to a promising outlook for market expansion in the region.
Region with highest CAGR:Asia Pacific is projected to hold the highest CAGR over the forecast period. It is a serious condition that affects a significant number of people in the region. Awareness campaigns and improved diagnosis have contributed to a better understanding of the condition, leading to increased demand for effective treatments. Competition among pharmaceutical companies, research institutions, and healthcare providers drives innovation and affordability in ARS treatments.
Key players in the marketSome of the key players in Acute Repetitive Seizures market include Bausch Health Companies Inc., UCB Pharma, Eisai Co., Ltd., SK Biopharmaceuticals Co., Ltd., Valeant Pharmaceuticals North America LLC, Sunovion Pharmaceuticals, GW Pharmaceuticals, Pfizer Inc., Marinus Pharmaceuticals, Neurelis, Inc., Sanofi, Novartis AG, Alexza and Veriton Pharma.
Key Developments:In May 2019, UCB declared that the U.S. FDA has permitted a New Drug Application for the company’s latest anti-epileptic drug (AED) NAYZILAM® nasal spray CIV. It is a benzodiazepine designated for the stereotypic incidents of recurrent seizure activity and acute treatment of intermittent that are different from a patient’s normal seizure form in person with epilepsy 12 years and older1.
In September 2018, Neurelis, Inc., a pharmaceutical firm based in San Diego, California, submitted a New Drug Application (NDA) to the FDA for VALTOCO as a treatment for epilepsy patients with acute repeated seizures.
Products Covered:
• Diastat Rectal Gel
• AZ-002
• NRL-1
• USL-261
• Other Products
Drug Types Covered:
• Benzodiazepines
• Barbiturates
• Antiepileptic Drugs (AEDs)
• Other Drug Types
Route of Administrations Covered:
• Intranasal Formulations
• Oral
• Intravenous
Distribution Channels Covered:
• Specialty Clinics
• Retail Pharmacies
• Hospitals
• Online Pharmacies
End Users Covered:
• Home Care Settings
• Clinics
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements